IL113191A - Pharmaceutical preparations containing trobloxacacin are derived for use against e. Pylori - Google Patents

Pharmaceutical preparations containing trobloxacacin are derived for use against e. Pylori

Info

Publication number
IL113191A
IL113191A IL113191A IL11319195A IL113191A IL 113191 A IL113191 A IL 113191A IL 113191 A IL113191 A IL 113191A IL 11319195 A IL11319195 A IL 11319195A IL 113191 A IL113191 A IL 113191A
Authority
IL
Israel
Prior art keywords
treatment
compound
gastric
pharmaceutically acceptable
formula
Prior art date
Application number
IL113191A
Other languages
English (en)
Hebrew (he)
Other versions
IL113191A0 (en
Inventor
Arthur E Girard
Thomas D Gootz
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of IL113191A0 publication Critical patent/IL113191A0/xx
Publication of IL113191A publication Critical patent/IL113191A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
IL113191A 1994-04-07 1995-03-30 Pharmaceutical preparations containing trobloxacacin are derived for use against e. Pylori IL113191A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22436294A 1994-04-07 1994-04-07

Publications (2)

Publication Number Publication Date
IL113191A0 IL113191A0 (en) 1995-06-29
IL113191A true IL113191A (en) 1998-02-08

Family

ID=22840341

Family Applications (1)

Application Number Title Priority Date Filing Date
IL113191A IL113191A (en) 1994-04-07 1995-03-30 Pharmaceutical preparations containing trobloxacacin are derived for use against e. Pylori

Country Status (14)

Country Link
US (2) US5728711A (ja)
JP (1) JP3205217B2 (ja)
KR (1) KR0145489B1 (ja)
CN (1) CN1117492A (ja)
AU (1) AU698850B2 (ja)
CA (1) CA2146414C (ja)
FI (1) FI951655A (ja)
HU (1) HUT71490A (ja)
IL (1) IL113191A (ja)
MY (1) MY115949A (ja)
NZ (1) NZ270890A (ja)
RU (1) RU2114615C1 (ja)
TW (1) TW420610B (ja)
ZA (1) ZA952839B (ja)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR970032861A (ko) * 1995-12-29 1997-07-22 김준웅 헬리코박터 피로리 제거용 약제 투여방법
US6391889B2 (en) 1996-07-12 2002-05-21 Daiichi Pharmaceutical Co., Ltd. Cis-substituted aminocyclopropane derivatives
ID20812A (id) 1997-07-09 1999-03-11 Takeda Chemical Industries Ltd Senyawa polyol, produk dan penggunaannya
HN1998000106A (es) 1997-08-01 1999-01-08 Pfizer Prod Inc Composiciones parenterales de alatroflaxacino
US7019142B2 (en) * 1998-01-16 2006-03-28 Pfizer Inc. Process for preparing naphthyridones and intermediates
EP1140979A1 (en) * 1999-01-07 2001-10-10 Takeda Chemical Industries, Ltd. Polyol compounds, their production and use
EP1121933A1 (en) * 2000-02-02 2001-08-08 Pfizer Products Inc. Premixed alatrofloxacin injectable compositions
US20060194748A1 (en) * 2005-02-28 2006-08-31 National University Corporation Nagoya University Methods for treating disorders induced by H. pylori infections and pharmaceutical compositions for the same

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3887353T2 (de) * 1987-10-12 1994-05-05 Capability Services Pty Ltd Behandlungsverfahren für magen-darm-krankheiten.
US5164402A (en) * 1989-08-16 1992-11-17 Pfizer Inc Azabicyclo quinolone and naphthyridinone carboxylic acids
GB9018603D0 (en) * 1990-08-24 1990-10-10 Smith Kline French Lab Compositions
US5116821A (en) * 1990-11-20 1992-05-26 The Procter & Gamble Company Sulfated glyceroglucolipids as inhibitors of bacterial adherence
GB9120131D0 (en) * 1991-09-20 1991-11-06 Glaxo Group Ltd Medicaments
TW276996B (ja) * 1992-04-24 1996-06-01 Astra Ab
WO1995008332A1 (en) * 1993-09-20 1995-03-30 The Procter & Gamble Company Use of triclosan phosphates for the treatment of gastrointestinal disorders due to heliobacter infection
JPH07101977A (ja) * 1993-10-05 1995-04-18 Kureha Chem Ind Co Ltd ホルモン作用を軽減した新規なエストラジオール誘導体及びその増殖因子阻害剤
JP3767831B2 (ja) * 1995-06-14 2006-04-19 木村 健 ヘリコバクター・ピロリ除菌用組成物

Also Published As

Publication number Publication date
MY115949A (en) 2003-10-31
JPH07285865A (ja) 1995-10-31
AU1630895A (en) 1995-10-19
KR950028771A (ko) 1995-11-22
ZA952839B (en) 1996-10-07
RU2114615C1 (ru) 1998-07-10
NZ270890A (en) 2001-03-30
HUT71490A (en) 1995-11-28
AU698850B2 (en) 1998-11-12
KR0145489B1 (ko) 1998-07-15
FI951655A (fi) 1995-10-08
RU95105169A (ru) 1997-01-20
JP3205217B2 (ja) 2001-09-04
IL113191A0 (en) 1995-06-29
US5728711A (en) 1998-03-17
CN1117492A (zh) 1996-02-28
FI951655A0 (fi) 1995-04-06
TW420610B (en) 2001-02-01
CA2146414A1 (en) 1995-10-08
CA2146414C (en) 1998-09-15
HU9501011D0 (en) 1995-05-29
US5900413A (en) 1999-05-04

Similar Documents

Publication Publication Date Title
US6080757A (en) Antibiotic quinolones and derivatives
JP4730634B2 (ja) ヘリコバクターピロリに対して抗菌活性を有するラクトバシルスアシドフィルスｈｙ２１７７、ラクトバシルスカセイｈｙ２７４３及びそれらを用いた乳酸菌製剤と発酵乳
JP4021951B2 (ja) 乳酸菌を有効成分とする抗胃炎剤、抗潰瘍剤および醗酵食品
JPH11503913A (ja) 流出ポンプ阻害剤
US5900413A (en) Treatment of H. pylori infections
US5674858A (en) Medicaments for treating gastrointestinal disorders
EP1340755A1 (en) Anti-helicobacterial agents
US20120040922A1 (en) Antibiotic macrocycle compounds and methods of manufacture and use thereof
KR100251888B1 (ko) 긴 사슬의 지방족 알콜을 가진 아실카르니틴 에스테르와 항박테리아 활성을 지닌 그의 약제조성물
EP0676199B1 (en) Use of trovafloxacin or derivatives thereof for the manufacture of a medicament for the treatment of H. pylori infections
US6242424B1 (en) Moenomycin and its derivatives for the production of pharmaceuticals, and pharmaceuticals containing moenomycin or its derivatives
AU2004297218A1 (en) Human anti-Pseudomonas-aeruginosa antibodies derived from transgenic Xenomouse
GB2289674A (en) Antibacterial naphthyridine
JP2010248261A (ja) 合成ラクトン処方物ならびに使用方法
US6271256B1 (en) Methods for controlling gram negative bacteria in mammals with bicyclo spiroether compounds
MXPA02005381A (es) Composiciones antibioticas de azalida.
KR20040030676A (ko) 락톤 포뮬레이션과 그 사용방법
US6174710B1 (en) Spirolaxine derivatives for treating gastrobuodenal diseases
US6380217B1 (en) Methods for controlling GGT-positive bacteria
MXPA97004182A (en) Antibiotics of quinolone and its deriva
CN116515102A (zh) 星型β-抗菌糖肽、其制备方法及应用
de Louvois et al. Moxalactam as an alternative to gentamicin in the treatment of clinically infected neonates
JPH11292763A (ja) 抗ヘリコバクター・ピロリ剤
JPH0296527A (ja) 抗潰瘍剤
JPH0977766A (ja) ４−アミノ−５−ピリミジンカルボン酸誘導体を有効 成分とする抗菌剤

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees